Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

  • There is currently no data for BMK

Share Premium Reduction

21 Mar 2023 17:33

RNS Number : 7702T
Benchmark Holdings PLC
21 March 2023
 

21 March 2023

 

Benchmark Holdings plc

("Benchmark" or the "Company")

Share Premium Reduction

21 March 2023

The Company announces that the cancellation of its share premium account (the "Capital Reduction"), which was approved by shareholders on 16 February 2023, is now effective. This follows the confirmation of the Capital Reduction by the High Court of England and Wales on 14 March 2023 and the registration of the Court order with the Registrar of Companies on 20 March 2023.

The Capital Reduction creates additional distributable reserves to the value of £394,235,072. The Company confirms that, following the Capital Reduction, the issued share capital of the Company remains at 739,277,469 ordinary shares of £0.001 each. The total number of voting rights in the Company also remains at 739,277,469.

Enquiries

 

For further information, please contact:

Benchmark Holdings plc

Tel: 0114 240 9939

Ivonne Cantu, Investor Relations

Numis (Broker and NOMAD)

Tel: 020 7260 1000

James Black, Freddie Barnfield, Duncan Monteith

MHP

Tel: 020 3128 8793 

Katie Hunt, Reg Hoare, Veronica Farah

benchmark@mhpgroup.com

 

About Benchmark

Benchmark is a market leading aquaculture biotechnology company. Benchmark's mission is to drive sustainability in aquaculture by delivering mission-critical products and solutions in genetics, advanced nutrition and health which improve yield, growth and animal health and welfare. Through a global footprint in 26 countries and a broad portfolio of products and solutions, Benchmark addresses the major aquaculture species - salmon, shrimp, sea bass and bream, and tilapia, in all the aquaculture regions around the world.

Find out more at www.benchmarkplc.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUAOBROUUOUAR
Date   Source Headline
3rd Apr 20174:32 pmRNSBlock Listing Six Monthly Return
9th Mar 20178:44 amRNSDirector Share Options and Issue of Shares
7th Mar 201710:39 amRNSResult of AGM
7th Mar 20178:00 amRNSContract Win
2nd Mar 20173:34 pmRNSHolding(s) in Company
1st Mar 20172:09 pmRNSHolding(s) in Company
23rd Feb 20177:00 amRNSHolding(s) in Company
22nd Feb 20174:35 pmRNSHolding(s) in Company
16th Feb 20177:45 amRNSDirector Dealings
24th Jan 20177:00 amRNSFinal Results
3rd Jan 20177:00 amRNSTotal Voting Rights
1st Dec 20167:00 amRNSDirector/PDMR Shareholding
29th Nov 20167:00 amRNSCapital Markets Day
25th Nov 20167:00 amRNSAppointment of Non-Executive Director
23rd Nov 20164:52 pmRNSHolding(s) in Company
26th Oct 20167:00 amRNSTrading Statement
12th Oct 20167:00 amRNSBlock Admission Application
10th Oct 201612:02 pmRNSBlock listing Interim Review
31st Aug 20167:00 amRNSBenchmark secures innovative new equine vaccine
12th Aug 201612:41 pmRNSHolding(s) in Company
11th Aug 20167:00 amRNSAcq of South American shrimp breeding programme
10th Aug 20163:37 pmRNSHolding(s) in Company
10th Aug 20161:40 pmRNSHolding(s) in Company
10th Aug 20161:33 pmRNSHolding(s) in Company
10th Aug 20161:29 pmRNSHolding(s) in Company
9th Aug 20163:26 pmRNSHolding(s) in Company
5th Aug 20167:00 amRNSPlacing of 47.3 million new ordinary shares
29th Jul 20167:00 amRNSDirectorate Change
19th Jul 20167:00 amRNSNew Seabass Vaccine Commences Field Trials
12th Jul 20167:00 amRNSBreeding & Genetics Contract Win
28th Jun 20167:00 amRNSHalf-year Report
3rd Jun 20167:00 amRNSChange of Adviser
27th May 20167:00 amRNSChange of Auditor
26th May 20167:00 amRNSTrading Update and Notice of Results
22nd Apr 201610:45 amRNSHolding(s) in Company
18th Apr 20169:40 amRNSIssue of Equity
22nd Mar 20169:07 amRNSBlocklisting Interim Review
10th Mar 201610:13 amRNSResult of AGM
5th Feb 20162:51 pmRNSDirector Dealings
2nd Feb 20167:00 amRNSFinal Results
7th Jan 201611:02 amRNSHolding(s) in Company
5th Jan 201612:08 pmRNSHolding(s) in Company
4th Jan 20163:04 pmRNSHolding(s) in Company
4th Jan 20163:00 pmRNSHolding(s) in Company
4th Jan 201611:18 amRNSHolding(s) in Company
4th Jan 201610:47 amRNSHolding(s) in Company
4th Jan 201610:43 amRNSHolding(s) in Company
4th Jan 201610:40 amRNSHolding(s) in Company
4th Jan 20169:26 amRNSHolding(s) in Company
4th Jan 20169:19 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.